ASCO 2024

The search for predicitve biomarkers continues

Prognostic value of ctDNA in therapeutic strategies;…

AI for the prediction of disease progression

Avelumab in early TNBC

Personalized neoadjuvant therapy for high-risk breast…

ctDNA analysis in monarchE

Ribociclib is also effective in N0 HR+/HER2− EBC

Advantage for node-negative patients

One step closer to chemo-free therapy for HR+/HER2+…

Reassuring and clarifying new data for CDK4/6…

Improvement for firstline treatment for patients with…

Eribulin, Trastuzumab, Pertuzumab in 1stL HER2+ mBC

Responder premenopausal

Triple positive mBC - chemotherapy unnecessary?

Heterogenity of ER+ disease

Leptomeningeal metastases in HER2+ mBC

Is there still a place for endocrine therapy in HER2+…

New data on the omission of chemotherapy in young…

ER-low: endocrine therapy necessary after all?

Broaden T-DXD as therapy standard for HER2low and…

Decreasing SG related toxicity with profilatic G-CFS

Novel ADC-ICI combination therapy

The ADC revolution continues - ctDNA takes the next…

HER2+ mBC 1stL T-Dxd

Sacituzumab tirumotecan - a new powerful ADC for…

Ultra low - ultra good?

Important OS benefit with T-Dxd in HER2+ mBC

T-DXD continues its impressive track record for MBC…

First-line inavolisib/placebo + palbociclib +…

Chemo-free regimen in HER2+ luminal breast cancer

Treatment beyond progression for CDK 4/6i

Chemo-free, CDK4/6 inhibitor-based combination active…

Already more in the 1stL?

CDK4/6 rechallenge

CDK4/6i effective in premenopausal patients as well

INAVO120 - updated results

La révolution de l'ADC se poursuit / ctDNA franchit une…

CDK4/6 rechallenge

Espansione dell'uso di T-DxD nelle pazienti con…

Importante beneficio en la supervivencia global con…

Regime senza chemioterapia nel carcinoma mammario…

Le traitement endocrinien a-t-il encore sa place dans…

Disminución de la toxicidad relacionada con la OS con…

Sacituzumab tirumotecan – nowy aktywny koniugat w…

Leczenie bez chemioterapii, oparte na inhibitorze…

C'è ancora posto per la terapia endocrina nel BC HER2+?

Is the metformin story over? How to treat HFNS…

Interesting data - but not practice changing

Focus on Quality of Life

Radionukleotides - the next step forward

The evolving role of PSMA-PET with new agents

mCRPC: Who benefits from which measures?

EMBARK demonstrates the importance of HRQoL benefit in…

RCT in mCRPC

Unveiling the Potential: PSMA-PET in Prostate Cancer…

Important QoL data

Exploring the CHAARTED TRIAL: Optimizing Treatment…

mCRCP CYCLONE 2 study

EMBARK: Quality of Life

Unlocking Insights: The ALLIANCE Trial redefining…

Deciphering EMBARK: Exploring Enzalutamide's Impact on…

EV-Pembro shows consistent outcome - caution with…

Modified FOLFIRINOX therapy as a good option for…

Quality of life not affected by i. v. Pembro

Biomarkers and long-term outcomes in pts with low tumor…

ctDNA as a biomarker in metastatic bladder cancer

Preoperative use of sacituzumab govitecan

MI-UC - News from EVP standard

ASCO 2024: Time for the rare GU tumors?

What to do with Cis Gem Nivo?

Effect of an immune diet on the outcome after radical…

The Role of Topoisomerase Inhibitors in the…

The future of sacituzumab govitecan

Interim analysis of the SURE-01/02 study

El futuro de sacituzumab govitecan

ASCO24: Bladder cancer highlights

El papel de los inhibidores de topoisomerasa en el…

ASCO 2024: momento para los tumores GU poco frequentes?

Evaluating risk criteria and monotherapy in mRCC

Advancing our understanding of biological mechanisms…

Advancing Our Understanding of Biological Mechanisms…

Combination is superior to monotherapy - how do we…

KIM-1 - old wine in new bottles

Combination therapies for chromophobe renal cell…

The never ending saga of biomarkers

Belzutifan in earlier lines in advanced ccRCC

Another breakthrough perioperative

KIM-1: Will have a major impact

Metastasized chromophobe RCC

Adjuvant KIM-1 as prognostic & predictive biomarker

New IMDC risk group - very favorable

Treatment of favorable prognosis mRCC patients:…

DFF332 a novel HIF inhibitor

NIVO+CABO: significantly longer therapy-free time

nccRCC

The search of the ideal biomarker in advanced renal…

Biomarker analysis of KN426 & CLEAR

La busqueda del marcador ideal en el cancer renal…

End of the story in EGFRm disease?

ctDNA predicts outcome in patients treated with…

Liquid biopsy in curative situation

4-year efficacy of Keynote-799 and ctDNA

Gamechanger in EGFR-mutated NSCLC

Osimertinib improves PFS in stage III

Stadium III EGFR+: now permanently Osimertinib?!

CheckMate 816: 4-year update

Confirmed efficacy of periop IO in N2 R-NSCLC

4y follow-up of CheckMate 816

Early change in SOC in EGFR+ LD-NSCLC

Le traitement adjuvant par osimertinib apres CTRT : …

Cambio temprano en el tratamiento estándar del EGFR+…

Update for EGFR-positive NSCLC

Lorlatinib with extraordinary data in ALK + NSCLC

TROP2-targeting ADCs: where a we heading?

ALK+ NSCLC - CROWN revisited

KRASG12C - the story continues

KRAS building on single agent therapy

ADCs - moving landscapes. Subgroups remain to be…

Confirmed efficacy of adagrasib in KRASG12C

ASCO 2024 highlights

BAY2927088 - Promising Her2-Inhibitor in NSCLC

Telehealth is just as effective as a face-to-face visit…

EGFR+ NSCLC - amivantamab-based combination therapy

Lorlatinib convincing in ALK mutation 1st line

The end for local therapy for oligometastatic disease

Subcut amivantamab - the future

Adagrasib for KRASG12C mutation 2nd line

ASCO 2024 highlights

ASCO 2024 highlights

BAY297088 - Inhibiteur Her2-Inhibitor dans le NSCLC

KRASG12C - het verhaal gaat verder

Het einde van lokale therapie voor oligometastatische…

Maintenance with durvalumab is the new SOC after…

New SoC for LD-SCLC

Finally, change for LS-SCLC

Tarlatamab shows activity in patients with brain…

Le traitement d'entretien avec le durvalumab est le…

Harsh to beat

Is adjuvant treatment still standard in macroscopic,…

10 years follow up - immunotherapy for BRAF-mutated…

Is the triplet ready for phase 3?

Stimulating new combination of two antibody-cytokine…

Personalized mRNA-vaccination: Practice changer of the…

Neoadjuvant immunotherapy treatment for melanoma

No differences in PFS between the two study arms

Promising Results: Triple combination therapy in…

Identifying patients with longterm benefits during…

TIL therapy for metastatic melanoma

New oncolytic immunotherapy (RP1) after PD-1 failure

Progress in neoadjuvant therapy with IO

A new therapy benchmark for brain-met melanoma patients

Triple checkpoint blockade - a new approach?

Impactful studies from ASCO 24 III: Cell-therapy

Lentigo maligna therapy

Longterm survival after adjuvant targeted therapy

Promising activity of brenetafusp in PD-L1 refractory…

Neoadjuvant intratumoral therapy with Daromun in…

Emerging rescue therapies for PD1 refractory melanoma

Vaccine in combination with nivolumab for PDL1…

A new triplet for metastatic melanoma

3-year update on mRNA vaccines in melanoma

Adjuvant therapy with dabrafenib and trametinib - final…

Impactful studies from ASCO 24 I: NADINA

mRNA vaccine plus pembrolizumab in adjuvant therapy

Intralesional therapy with Daromun

Consolidation of the use of IO in clinically detectable…

Survival data for TT with dabrafenib and trametinib

Consolidación del uso de IO en melanoma en estadio III…

Risultati promettenti: Tripla terapia di combinazione…

No hubo diferencias en la PFS entre los dos brazos del…

New therapeutic approaches: Get over PD1 resistances?

New MOA in r/m HNSCC

New insights in localized HNSCC

New idea: anti-digest for EC?

De-escalation in ovarian cancer?